Pancreatic β Cell Mass Death by Husnia I. Marrif & Salma I. Al-Sunousi
REVIEW
published: 06 April 2016
doi: 10.3389/fphar.2016.00083
Frontiers in Pharmacology | www.frontiersin.org 1 April 2016 | Volume 7 | Article 83
Edited by:
Weien Yuan,
Shanghai JiaoTong University, China
Reviewed by:
Martin C. Michel,
Boehringer Ingelheim Pharma GmbH
& Co. KG, Germany
Mahin D. Maines,
University of Rochester School of
Medicine, USA
Hong Zhan,
University of Wisconsin-Madison, USA
*Correspondence:
Husnia I. Marrif
husnia.marrif@mail.mcgill.ca
Specialty section:
This article was submitted to
Integrative and Regenerative
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 14 October 2015
Accepted: 14 March 2016
Published: 06 April 2016
Citation:
Marrif HI and Al-Sunousi SI (2016)
Pancreatic β Cell Mass Death
Front. Pharmacol. 7:83.
doi: 10.3389/fphar.2016.00083
Pancreatic β Cell Mass Death
Husnia I. Marrif 1* and Salma I. Al-Sunousi 2
1Department of Pharmacology, Faculty of Medicine, University of Benghazi, Benghazi, Libya, 2Department of Histology and
Anatomy, Faculty of Medicine, University of Benghazi, Benghazi, Libya
Type two diabetes (T2D) is a challenging metabolic disorder for which a cure has not
yet been found. Its etiology is associated with several phenomena, including significant
loss of insulin-producing, beta cell (β cell) mass via progressive programmed cell death
and disrupted cellular autophagy. In diabetes, the etiology of β cell death and the role
of mitochondria are complex and involve several layers of mechanisms. Understanding
the dynamics of those mechanisms could permit researchers to develop an intervention
for the progressive loss of β cells. Currently, diabetes research has shifted toward
rejuvenation and plasticity technology and away from the simplified approach of hormonal
compensation. Diabetes research is currently challenged by questions such as how to
enhance cell survival, decrease apoptosis and replenish β cell mass in diabetic patients. In
this review, we discuss evidence that β cell development and mass formation are guided
by specific signaling systems, particularly hormones, transcription factors, and growth
factors, all of which could be manipulated to enhance mass growth. There is also strong
evidence that β cells are dynamically active cells, which, under specific conditions such
as obesity, can increase in size and subsequently increase insulin secretion. In certain
cases of aggressive or advanced forms of T2D, β cells become markedly impaired,
and the only alternatives for maintaining glucose homeostasis are through partial or
complete cell grafting (the Edmonton protocol). In these cases, the harvesting of an
enriched population of viable β cells is required for transplantation. This task necessitates
a deep understanding of the pharmacological agents that affect β cell survival, mass,
and function. The aim of this review is to initiate discussion about the important signals
in pancreatic β cell development and mass formation and to highlight the process
by which cell death occurs in diabetes. This review also examines the attempts that
have been made to recover or increase cell mass in diabetic patients by using various
pharmacological agents.
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INTRODUCTION
Diabetes mellitus (DM) is a cluster of chronic metabolic disorders triggered by insulin deficiency.
The incidence and prevalence of DM are high and are steadily increasing worldwide (Koloverou
et al., 2014; Samuel-Hodge et al., 2014; Anjana et al., 2015; Luo et al., 2015; Pati et al., 2015;
Srinivasan and Florez, 2015; Tancredi et al., 2015). TheAmericanDiabetes Association has classified
diabetes into four categories: type one diabetes (T1D), type two diabetes (T2D), Gestational diabetes
mellitus (GDM), and other specific types of diabetes (American Diabetes Association, 2015). In
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T1D, there is a complete failure of the pancreas to produce
insulin. In contrast, in T2D, there is a fundamental change in
insulin secretion and in insulin receptor dynamics.
In T2D research, a plethora of studies have sought to rescue
pancreatic β cells and maintain insulin secretion (Butler et al.,
2007). Insulin is secreted by the pancreas, an organ that hosts
various cell lineages, many of which are involved in endocrine
or exocrine functions. The present review, however, focuses on
the β cells of the islets of Langerhans, which are responsible for
insulin secretion.
Current research in diabetes reveals that a significant
reduction in pancreatic β cell populations is the leading cause
of the decrease in insulin production in T2D. A significant
decrease in β cell mass was first reported when pancreatic
samples from autopsies of diabetic patients were compared with
samples from non-diabetic subjects (Butler et al., 2003). Available
studies also suggest that the decline in β cell mass precedes the
onset of diabetes by almost a decade. Furthermore, studies show
that at the time of diagnosis, diabetic patients seem to have
already lost ∼50% of their pancreatic β cells. This loss is a slow
process that ends with the individual experiencing full-blown
diabetes. The mechanism by which β cell mass decreases is still
under investigation; however, the available evidence suggests that
hyperglycemia induces apoptotic cell death, whichmay be the key
pathological mechanism of diabetes.
Events affecting the β cell population are classified into two
groups. The first group is composed of factors influencing β
cell lineage expression, neogenesis, and maturation (molecular
events). The second group includes factors causing mature β cell
injury and death (cellular events). Unfortunately, the biological
processes are more complex than these classifications imply;
for instance, metabolic factors that cause direct cell injury or
death can also affect the neogenesis and lineage commitment
of β cells. This review focuses on the factors that affect β cell
mass.
OVERVIEW OF PANCREAS
DEVELOPMENT AND FUNCTIONS
Since the discovery of insulin deficiency in diabetic individuals,
endocrine researchers have made it a priority to acquire
knowledge about the development of the pancreas, its cellular
endocrinology, and its pathophysiology an utmost priority.
The development of the pancreas commences with the
budding of the ventral and dorsal region from the embryogenic
layer of the endoderm. Most of our collective knowledge of
cellular pancreatic growth comes from studies on rodents; with
the exception of a few deviations, rodents exhibit pancreatic
development quite similar to that in humans. The budding of
the pancreas in a mouse starts at day E9.5. The ductal system
is formed before E13; at that point, cells begin to differentiate
(Gao et al., 2008). One of the most important signals in this
stage is initiated by the homeobox transcription factor (Pdx1) in
the pancreas and duodenum. The pancreas then proceeds to the
second stage of cellular maturity or lineage commitment, with
cells terminally differentiating into either endocrine or exocrine
cells. This phase is guided by a specific set of transcription factors
and growth signals (Gittes, 2009).
CELLULAR DEVELOPMENT
Much like that of any other organ, the embryonic development
of the pancreas establishes the setting for proper cell maturation
and function. Cells influenced by environmental and genetic
factors can travel along any of the following pathways:
generation, proliferation, differentiation, and possibly full lineage
commitment, quiescence state (dedifferentiation), or mutation.
The above possibilities are governed by the presence of
endogenous and/or exogenous signals, which can include
hormones, growth factors, neurotransmitters, intermediate
metabolites, or transcription factors (Bonner-Weir et al., 2010).
Numerous transcription factors act as key signals for the
proliferation and terminal differentiation of pancreatic cells.
THE MATURE PANCREAS
Upon inspection of themature organ, a gross view of the pancreas
shows a simplified ductal system surrounding the head, body,
and tail of the pancreas, with scattered islets of cells at different
sites. The cellular structure of the pancreas, however, is far more
complex. This level of detail exhibits a complex “community”
of cells with variable shapes and functions. Pancreatic products,
whether hormonal or non-hormonal, are secreted by distinct
populations of cells, each at a specific location and with a
specific function (Table 1). Ultimately, cells in the pancreas can
be classified as either endocrine or exocrine cells, depending on
their function.
PANCREATIC EXOCRINE CELLS
Acinar Cells
The exocrine functions of the pancreas are carried out by
exocrine cells, also known as acinar cells. The name acinar,
or acini as a group, refers to the aggregation of these cells
into clusters. The main physiological function of acinar cells
is to secrete pancreatic digestive enzymes (e.g., alpha-amylase,
proteases, and lipases). The mixture is then emptied into the
duodenum via the ductal system. Regarding the contribution
of these cells to pancreatic cell development and lineage
commitment, acinar cell function goes well beyond only
secretion. For example, these cells are involved in regulating the
neogenesis of islet cells (Table 1).
Duct Cells
The ductal structure of the pancreas is also formed by epithelial
cells derived from the pancreatic primordia. These duct cells are
connected in a chain-like structure to form convoluted tubing
throughout the pancreas, and their main physiological function is
to secrete mucus and bicarbonate. Current research suggests that
the function of duct cells exceeds that of their exocrine duties,
much like the function of acinar cells. Given their important
role in the regenerative process in the pancreas, duct cells are
discussed in greater detail at a later point in this review.
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TABLE 1 | Pancreatic cell populations and functions.
Cell Secretion Target Function
ENDOCRINE CELLS OF THE PANCREASES
A α (alpha) Glucagon Liver Increases plasma glucose
Glucagon-like peptides (GLP-1) and (GLP-2) Pancreas Increases insulin secretion and sensitivity. It
decreases glucagon secretion
B (Beta) Insulin All sites Decreases plasma glucose
Amylin or Islet Amyloid Polypeptide (IAPP) Pancreas Decreases Pancreatic enzymes
Gut Decreases gastric emptying
D δ (Delta) Somatostatin Pancreas Inhibits insulin and glucagon secretion
F PP Pancreatic polypeptide Pancreas Regulates secretion
(ε) Epsilon Ghrelin (AG). Unacylated Ghrelin (UAG) Pancreas Inhibits insulin release and increases appetite
Obestatin Pancreas Increases insulin release and decreases appetite
EXOCRINE CELLS OF THE PANCREAS
Acinar cells Alpha-amylase, proteases and lipases Gut Promotes digestion
Islet neogenesis associated protein (peptide of 175
amino acids)
Pancreas Induces β cell neogenesis
Duct Cells Forming ductal structure, secrete mucus,
bicarbonate
Gut Promotes digestion and regenerative process
PANCREATIC ENDOCRINE CELLS
Islets of Langerhans: Development,
Function, and Manipulation
The pancreas contains exocrine acinar and ductal cells, and
endocrine cells that form the islets of Langerhans. The islet cells
can be classified into five distinct glandular cell types: alpha
(α), beta (β), delta (δ), epsilon (ε), and F cells (Table 1). In
humans, the pancreas contains an estimated onemillion islet cells
(Bonner-Weir et al., 2010), and the islets occupy ∼1–1.5% of the
organ’s volume. The exocrine cells occupy ∼95% of the pancreas
in adult humans and rodents (Hara et al., 2007).
Rodents are the most widely used experimental model for
studying pancreatic cells. However, there are a few notable
differences between the islet cells of rodents and humans.
For instance, during the developmental stages of humans and
rodents, β cells are found in the core of the islets and are
surrounded by δ and α cells (Steiner et al., 2010). In rodents,
this basic structure continues to exist in adults. In adult humans,
however, β cells are found scattered throughout the pancreas,
although there is a high density in the anterior portion of the
pancreas head (Yesil and Lammert, 2008; Steiner et al., 2010).
There is also evidence that human and rodent islets are
equipped with different glucose sensor systems. Research shows
that human islets use Glut-1 and Glut-3, whereas Glut-2 is the
main glucose transporter in rodents (McCulloch et al., 2011;
Rorsman and Braun, 2013). Different transporters have different
affinities (Km-value) for glucose; this difference is crucial, as it
eventually influences insulin release.
Another important difference is growth rate; in vitro, human
β cells grow at a much slower rate than do those of rodents
(Szkudelski, 2001).
Estimates of β cell content are essential for diabetes research,
as these estimates can be used in cell rescue therapy and
grafting. Current studies show variable estimates of β cell
content; therefore, it is essential to consider the differences
between the experimental models used (e.g., species, age, and
technical procedures) and the measures used to describe β cell
content, such as volume or fraction. It has been reported that
the adult human pancreas contains nearly one million islets
(Matveyenko and Butler, 2006; Rorsman and Braun, 2013). In
addition, a recent study using a combination of light and electron
microscopy reported that 73.6± 1.7% of human islet cells were β
cells (Pisania et al., 2010).
β Cell Proliferation vs. Differentiation
Rodent studies suggest that the fetal stage is the most critical
period in pancreatic β cell mass formation. At this point, islet β
cells start to multiply in response to growth factors, hormones
and, probably, critical signals from the autonomic nervous
system (Kiba, 2004). During lineage formation or differentiation,
cells undergo three stages of development—pre-differentiation,
proto-differentiation, and differentiation (Figure 1)—and each
stage is regulated by specific signals. Islets contain five cell
lineages, all of which originate from endodermal progenitor cells,
and the development of these lineages is guided by either specific
signals or common signals.
Some growth signals have a well-defined role in differentiation
and proliferation (Table 2); in most cases, however, the exact
functions of growth signals are still obscure (Estefanía et al.,
2012). In addition to domestic cycle cell regulators, some local
signals have been found to affect β cell differentiation and
phenotypes (Table 2). One key determining factor in β cell
fate is the Notch signaling pathway. It has been suggested
that the Notch 1 receptor, which is expressed in many of the
lineages found in islets, can halt exocrine and endocrine cell
differentiation, with endocrine cell differentiation being essential
for cells to acquire insulin-producing and insulin-sensing
properties.
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FIGURE 1 | Life cycle of β cells starts at the embryonic germinal stage where pre-differentiated cells changed into proto-differentiated stage under a
specific signal. Thereafter, cells express Notch protein which bind to Notch receptor and activate downstream genes, and cells become exocrine progenitors. Cells
which lack Notch protein expression, proceeds to form subset of endocrine progenitor cells which continue to differentiate into alpha (α), epsilon (ε) or to beta (β), and
delta (δ) cells. In the presence of the transcriptional signals above, beta (β), and delta (δ) cells continue differentiation to become β cells which eventually mature to
insulin producing cells.
FACTORS AFFECTING β CELL
DEVELOPMENT
Notch Signaling Pathway
The Notch family of receptors are transmembrane transcription
factors. The activated intracellular domain of Notch family
members interacts with the DNA-binding protein RBP-Jk,
thereby activating the expression of the basic negative helix–
loop–helix (bHLH) HES genes. This, in turn, represses the
expression of downstream target genes (Ehebauer et al., 2006).
The expression of Notch proteins in differentiated cells inhibits
the phenotyping of certain cells in their vicinity via a process
called lateral inhibition. Cells that do not respond to the Notch
signal undergo differentiation (Murtaugh et al., 2003).
Notch signaling is the only factor for which there is sufficient
evidence to show that it can decide the fate of pancreatic cells. In
the absence of the Notch signal, β cells commence differentiation,
developing the properties of mature β cells, such as the expression
of Glut-2, Glut-1, and glucokinase, as well as the secretion of
insulin. When the Notch signal is expressed at a normal level,
cells tend to differentiate into exocrine cells. A general outline of
the factors that affect cell differentiation is illustrated in Figure 1.
Lineage studies have identified other factors that are associated
with β cell lineage development, such as Mafb, Isl-1, Pax6,
and Pax-4, HIxb9, NKx2.2, and Nkx6.1. As noted above, some
factors are common regulators of the islet’s lineages; however,
the quantities expressed in each lineage are critical for specific
lineage’s execution.
PROGENITOR CELLS
Discussion about the role of neogenesis began when studies
reported that the ductal cells surrounding the islets can generate
β cells and likely other types of cells (Lipsett and Finegood, 2002;
Song et al., 2004; Gunasekaran et al., 2012). The ability of β cells
to proliferate from mature cells or other cell lineages initiated
intense scientific debate and curiosity.
In short, neogenesis, or the regeneration of endocrine β
cells, occurs within a cluster of epithelial exocrine duct cells.
The process commences when a subset of endocrine progenitor
cells, buried within the ductal cells, starts to express a lineage
marker known as Neurogenin 3 (Ngn3) by a process known as
“budding.” Cells then separate from the ductal chain to form
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TABLE 2 | Signals that affect pancreatic development and growth.
Signal mediator Location and note References
Homeobox HB9 (Hlxb9) Dorsal region of pancreas; endocrine and exocrine
cells; involved in β cell differentiation
Li et al., 1999.
Pancreas transcription factor 1 complex (Ptf1a) Ventral region and pancreas; endocrine and exocrine
cell differentiation
Schaffer et al., 2010
bHLH transcription factor 1 (Hes1) Transcriptional repressor; keeps progenitor cells
undifferentiated
Jensen et al., 2000
bHLH transcription factor Mist1 Ventral region and pancreas; endocrine and exocrine
cell phenotyping
Pin et al., 2001
Epidermal growth factor (EGF) Hepatocyte growth
factor (HGF) Platelet-derived growth factor (PDGF)
Transforming growth factor alpha (TGF-alpha) and
insulin
Stimulates progenitor cell proliferation via receptor
tyrosine kinases
Yesil and Lammert, 2008
Insulin-like growth factor (IGF-1 and 2) Stimulates progenitor cells Bouwens and Rooman, 2005
Homeoprotein Isl-1 (Islet-1) Stimulates the development of the dorsal pancreatic
bud; β cell differentiation and proliferation
Du et al., 2009
Neurogenin 3 (Ngn-3) bHLH family; stimulates endocrine cell differentiation Gradwoh et al., 2000; Song et al.,
2004; Gunasekaran et al., 2012
Homeobox Protein Nkx-6.1 (Nkx6.1) and
Homeobox Protein Nkx-2.2 (Nkx2.2)
β cell differentiation Oster et al., 1998
Paired box gene 4 (Pax-4) Transcriptional repressor for alpha cells and enhancer
for β cells in early development
Smith et al., 1999
Paired box gene 6 (Pax-6) β cell differentiation and function Hart et al., 2013
Pancreatic and duodenal homeobox 1 (Pdx-1)/
insulin promoter factor-1
β cell differentiation and function Hui and Perfetti, 2002
Growth hormone (GH) β cell proliferation Nielsen et al., 1989
Prolactin (PRL) β cell differentiation and morphogenesis Auffret et al., 2013
Placental lactogen (PL) β cell proliferation and phenotype Fleenor et al., 2000
Parathyroid hormone-related protein (PTHrP) β cell differentiation and proliferation Vasavada et al., 1996
Gastrin Neogenesis and transdifferentiation Rooman et al., 2002
Glucose-dependent insulinotropic polypeptide (GIP) Reduce β cell death (anti-apoptotic) and modulate
function
McIntosh et al., 2009
Glucagon-like peptide 1 (GLP-1) β cell proliferation Buteau et al., 2003
Cyclin D1 and D2 β cell proliferation Kushner et al., 2005
Cdk4 β cell proliferation Martín et al., 2003
the characteristic aggregates of insulin-secreting islets (Figure 2).
Further studies have reported that the progenitor cells can give
rise to all lineages of pancreatic endocrine cells, including alpha
(α), beta (β), and epsilon (ε) cells (Cabrera et al., 2006).
NEUROGENIN-3
The protein Neurogenin was first identified in both mice and
Xenopus (Ma et al., 1996). The family includes Neurogenin-1
(Ngn1), Neurogenin-2 (Ngn2), and Neurogenin-3 (Ngn3).
Whereas, Ngn1 and Ngn 2 were identified in the central
nervous system, Ngn-3 is localized in pancreatic endocrine cells.
Neurogenins are transcription factors that control the expression
of large sets of downstream genes that are directly involved in
neogenesis (Rukstalis and Habener, 2009).
Neurogenin belongs to the family of basic helix-loop-helix
(bHLH) transcription factors; several members of this family are
factors that influence differentiation and sub-lineage formation
(Sommer et al., 1996). Neurogenin is one of the earliest regulators
and determinants of neurogenesis in vertebrates. Pancreatic
Notch proteins control Ngn3 expression, and the Ngn3 signal
controls several downstream transcription factors, including
Nkx2.2, Pax-4, and NeuroD. All of the signals noted above
are critical genes for β cell differentiation and phenotyping
(Figure 1). Lineage tracing and commitment studies demonstrate
that the expression of Ngn3 in progenitor cells is transient and
that the amount expressed is critical for cell lineage commitment
(Rukstalis and Habener, 2009).
CELL LINEAGE TRACING
Cell lineage tracing is a technique designed to detect the presence
of a particular lineage. One of the most widely used genetic
tools is Cre-lox recombination, or site-specific recombinase
technology. This technology involves the recombinase enzyme
Cre, which recombines a pair of short target sequences, called lox
sequences. This system allows the user to insert or delete gene
markers, which can then be detected during cell development;
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FIGURE 2 | Immunohistochemistry of islet markers for morphogenesis
including; matrix metalloproteinase-2 (MMP-2), cytokeratin 19 (CK19)
and insulin. MMP-2 and Ck19 appeared in A and B sections (green). Insulin
positive cells (Red) budding from the ducts appeared in section close to ducts
(B). Adapted from Aye et al. (2010). Copyright © 2010 by SAGE Publications.
Reprinted with permission from SAGE Publications.
it is widely used for tracing pancreatic β cells (Wajchenberg,
2007). New techniques are also available, such as injecting dye
into specific cells via viruses (Xiao et al., 2014).
β CELL MASS FORMATION
In rodents, the process of β cell mass formation continues at a
high rate in the fetal and newborn stages; this mass formation
is followed by a significant slowdown in cell proliferation as
rodents age, and a similar process occurs in human pancreatic
development. Studies in mice using mitotic indexes have
estimated that 10–20% of β cell mass is formed by simple cell
division (Swenne and Eriksson, 1982). Mitosis comes to a halt
when mature cells that secrete insulin are detected in the islet,
and this stage represents the terminal differentiation stage of β
cells (Murtaugh et al., 2003).
Approximately 80% of β cell mass formed during the
fetal stage is thought to result from the differentiation of
“undifferentiated” progenitor cells and/or from the conversion of
non-endocrine cells into endocrine cells (Bouwens and Rooman,
2005). Studies on animals demonstrate that in adults, β cell mass
increases mainly via a β cell lineage replication process rather
than by conversion or neogenesis (Dor et al., 2004).
This observation is critical because it limits the search for a
source of replenishment of β cells. Apoptosis plays a detrimental
role in β cell mass formation. During the neonatal developmental
stage, β cells in pigs, humans, and rodents undergo a period
of transient apoptosis that ultimately limits the number of β
cells that is capable of multiplying at more advanced stages of
growth (Bouwens and Pipeleers, 1998). Another factor that can
modulate pancreatic β cell mass is, in quantitative terms, the
number of bulk progenitor cells in the pancreas that enters the
quiescent stage and never differentiates; currently, in the context
of diabetes, this process is described as the dedifferentiation of β
cells (Ziv et al., 2013).
In summary, humans are born with a limited number of β
cells, and those cells preferentially increase their mass through
mitosis, if needed. Obesity is one condition that can result in an
increase in β cell mass (Kloppel et al., 1985; Plesner et al., 2014).
However, the factors and signals that control the epigenetics of
β cell growth and death in obesity are still unclear and require
further investigation (Tennant et al., 2013).
COLLECTIVE CELLULAR GROWTH
The growth of pancreatic cells seems to be part of a collective
community process in which communication is essential for
organ development and maturation. Animal studies suggest that
neighboring cells can influence each other’s mass via several
mechanisms. For instance, a study by Plesner et al. (2014)
reported an intriguing autoimmune destructive process that
was triggered by pancreatic α cells neighboring β cells, which
ultimately resulted in the reduction of β cell mass and the
appearance of hyperglycemia.
Another example is the presence of a small peptide secreted
by pancreatic acinar cells, known as “islet neogenesis-associated
protein” (INGAP). INGAP is amember of the Reg protein family,
which can induce β cell neogenesis and proliferation (Tam et al.,
2002). It has been observed that the incubation of the INGAP
peptide with human adipose tissue-derived stem cells leads to the
differentiation of fat cells into islet-like clusters. Moreover, when
these islet-like clusters were implanted into a rat model of T2D,
the transplanted tissue improved the glycemic index and diabetic
symptoms (Ren et al., 2014).
In a conditional transgenic model in which INGAP was
specifically expressed in exocrine pancreas cells, mice showed
normalized glycemic indices and exhibited improved responses
to hyperglycemia following a diabetogenic dose of streptozotocin.
The protective effect of INGAPmight bemediated by different
mechanisms, which could include the reduction of oxidative
stress as well as INGAPmight have pleiotropic properties (Chang
et al., 2011). Recently, research on INGAP has generated interest
in β cell exogenesis and the development of amechanism through
which insulin secretion can be maintained. There is evidence that
INGAP is also effective in clinical settings. Trials have reported
that the INGAP peptide improves glycemic index and increases
insulin production in patients with T2D (Barbosa et al., 2006;
Lipsett et al., 2007; Wang et al., 2010). As this peptide also affects
the way in which the body uses insulin, the same beneficial
effects were reported in T1D patients. Several new clinical trials
to investigate this peptide are currently registered with the US
government.
TRANSDIFFERENTIATION
Transdifferentiation is the technical term for the process of
generating β cells from other cell lineages. Scientifically, the
concept of converting previously committed lineages to insulin-
secreting β cells seems rather daring, and the field is still
evolving. Animal models and lineage tracing have provided
strong evidence for the transdifferentiation of adult cell lineages,
such as duct cells (Bonner-Weir et al., 2008) and pancreatic acinar
cells, into β cells (Minami and Seino, 2008). At present, acinar cell
research seems to be the most promising for β cell regeneration;
however, this should not be confused with research in which stem
Frontiers in Pharmacology | www.frontiersin.org 6 April 2016 | Volume 7 | Article 83
Marrif and Al-Sunousi β Cells Mass
cells are isolated and genetically altered to become β cells (Ren
et al., 2014).
YAMANAKA FACTORS
One of the most intriguing recent discoveries in the field of
cell biology is the development of the induced pluripotent
stem cell (iPSC) protocol. The original protocol involved
the introduction into adult cells of four genes that encode
the following transcription factors: KLF4 (Kruppel-like factor
4), Oct-4 (octamer-binding transcription factor 4), SRY (sex
determining region Y-box 2), and Myc (c-Myc). This cocktail
converts adult cell lineages into pluripotent stem cells (Takahashi
and Yamanaka, 2006). The mere concept of transforming
mature, committed cells into pluripotent stem cells that can be
manipulated to grow into any lineage is bold and innovative. It
reflects the unlimited possibilities of cell manipulation and the
ability of cells to be transformed into any lineage.
For this discovery, a deserving Shinya Yamanaka shared
the Nobel Prize in Physiology or Medicine in 2012. Since
the Yamanaka protocol was published, several studies have
demonstrated the possibility of manipulating adult cells into
insulin-producing cells (Thatava et al., 2013; Shaer et al., 2015).
The protocol to produce rich β cell cultures is still being refined
and is not without hurdles. For instance, culture contamination
and high rates of apoptosis are two of the many challenges (Ziv
et al., 2013).
MATURE HUMAN β CELLS
The breakthrough by Yamanaka described above opened the
door to research into “pancreatic plasticity” and to transcription
factors other than the ones he specified that could manipulate cell
neogenesis. Currently, the list of transcription factors includes
Foxo1, Zbed6, Pdx1, Ngn3, MafA, Pax4, PPRβ/δ, and Arx, as well
as proteins such as Txnip and Sh2b1 (Collombat et al., 2009).
Mature β cell proliferation under simulated physiological
condition is highly controversial and many studies reported
contradictory results. For instance, it has been observed that
when β cells are isolated from young mice (8 weeks old) and
are incubated with human growth hormone and liraglutide,
a long-acting glucagon-like peptide-1 receptor agonist that is
approved by the FDA for T2D treatment, the result is a rich
and highly proliferated mass of insulin-secreting cells. Under the
same experimental conditions, β cells cultured from adult human
donors (ages 16–64) failed to show any proliferation (Parnaud
et al., 2008). It seems that adult human cells have a limited
capacity for proliferation. Furthermore, genetic and tracing
studies suggest that the conversion of cells and the presence of
stem cells at the adult stage are limited or non-existent. The only
exceptions to this process are the pancreatic acinar cells, which
are direct progeny of embryonic multi-potent progenitor cells
(Bonner-Weir et al., 2010). Under special circumstances such as
obesity, the β cell mass has been shown to have the ability to
increase in size. After birth, the proliferation of pancreatic β cells
is assumed to be limited; however, a substantial increase in β cell
mass, by up to 50%, has been observed in obese subjects (Kloppel
et al., 1985).
This unique process is considered to be a compensatory
mechanism for hyperglycemia and decreased β cell mass. It
may also be evidence for the presence of either a subset of
β cells that has the capacity to proliferate or a “magic bullet”
factor that forms in response to obesity. Accordingly, questions
have arisen regarding the source of the β cell increase and the
guiding signals that could lead β cells to proliferate in obese
individuals (Ferrannini et al., 2004; Bouwens and Rooman, 2005).
Yamanaka’s protocol and other similar in vitro observations
provide opportunities to harvest rich β cell masses that could be
used for pancreatic tissue regrowth and transplantation to treat
diabetic patients.
β CELLS AND DIABETES
The main function of pancreatic β cells is to sense insulin
needs and produce enough hormones to decrease the amount
of glucose to its physiological level, regardless of when food
was last ingested. The pathophysiology of diabetes commences
when the insulin level is inadequate to decrease the blood
glucose level and the patient develops hyperglycemia. T1D is
defined as autoimmune destruction of pancreatic β cell mass,
and its management is centered around insulin replacement,
maintaining tissue sensitivity to insulin and controlling body
weight.
The pathophysiology of T2D is different from that of T1D
and is a combination of a reduction in β cell mass and an
increase in insulin resistance. The reduction in β cell mass
has been confirmed in animal models of diabetes and obesity.
Whether β cell destruction is achieved by chemicals or by
genetic manipulation, as in transgenic and knockout models,
the endpoint is a reduction in β cell mass and hyperglycemia
(Marrif et al., 1995; King, 2012). Studies using animal models
have shown that symptoms of glucose intolerance, and eventually
hyperglycemia, appear when the density of β cells in the pancreas
falls below the threshold value of 10 million per kilogram of
body weight (Wang et al., 1996). The most successful animal
models used for studying β cell mass injury and generation are
the duct ligation models. It has been reported that when 90% of
the pancreas is resected, a remarkable hyperglycemia is produced
and is followed by a significant regeneration of the pancreas
(Bonner-Weir et al., 1983).
The regenerative process observed in this model starts as
early as 60 h after the procedure. The ligation model (in
which the tail of the pancreas is ligated) leads to a significant
decrease in pancreas size (50–60%), which eventually leads to
a nearly doubled β cell mass in the tail area; 60% partial-
pancreatectomy in mice evokes a similar regenerative process
(Peshavaria et al., 2006). This unique restoration process is
characterized by an increase in β cell and alpha cell populations
and islet clusters, as well as an upregulation of glucose transporter
two (GLUT2) in ductal cells. Based on tracing methods, β cell
neogenesis is attributed to a significant increase in ductal cell
proliferation (Wang et al., 1995). Human clinical cases have also
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provided evidence that in the event of a tumor or pancreatitis,
pancreatectomy can produce a specific regenerative process that
restores β mass homeostasis (Schlegel et al., 2000).
Other models can also be used to study β cell mass damage
and regeneration, such as the chemical ablation of β cell mass or
genetically manipulated models. The latter type of model is more
useful for studying β cell regeneration, as the timing of β cell
mass ablation can be controlled; examples are the doxycycline-
induced expression of diphtheria toxin in a β cell model and the
diphtheria toxin receptor-RIPmousemodel. There are additional
knockout and transgenic models that target specific genes (King,
2012). Considering all of the evidence for β cell mass reduction in
type 2 diabetes, the collective challenge now for diabetes research
is to find a way to increase β cell mass quantitatively.
DIABETES INDUCES β CELL DEATH
The most critical clinical study of the pathophysiology of
diabetics is that of Butler et al. (2003). The authors collected 124
post-mortem human pancreatic samples, including samples from
individuals who had been diagnosed with T2D, non-diabetic
individuals, individuals with impaired fasting glucose levels, and
lean individuals with diabetes. They investigated the following
parameters: the frequency of apoptosis and replication, the β
cell/islet volume, and new islet formation (Butler et al., 2003).
Their results offered the first glimpse of the human pancreas
after the onset of diabetes. Their results are summarized as
follows: they found that a significant reduction in β cell volume
by ∼40–63% (P < 0.05) takes places in diabetics and those with
glucose intolerance compared with that of non-diabetics.
The study also reported two important observations. First,
there is a significant increase (P < 0.05) in the frequency of
apoptosis, representing a staggering three- to ten-fold increase
in apoptotic cell death in diabetic patients. Second, they
found evidence of β cell neogenesis or proliferation within the
pancreatic ductal system in all the groups that were tested. The
study is particularly relevant because it is the largest human
study to date that has shed light on the mechanism by which β
cell death occurs in diabetes. It is also the first study to provide
evidence that the regeneration of β cells in the human pancreas
is possible.
There is further evidence supporting the notion that the β
cell population is a mass that effectively responds to increases
in demand through increases in proliferation. An earlier study
of human pancreatic autopsies showed an increase in β cell
mass of ∼40% in both obese T2D and obese non-diabetic
individuals (Kloppel et al., 1985). The increase in β cell mass
in obese individuals and diabetic individuals is considered a
compensatory mechanism (Kloppel et al., 1985; Butler et al.,
2003). Chronic exposure to hyperglycemia causes β cell insults
leading to cell death, and the body compensates for the lost
cells by increasing the β cell mass. This cycle continues until the
ability of the pancreas to generate new cells is exhausted. Current
research describes the rate of β cell volume reduction in diabetes
as a slow and ongoing process, and it is estimated that β cell death
in diabetes probably begins 10–12 years before an individual is
diagnosed (Wajchenberg, 2007).
SOPHISTICATED CELL DEATH CAUSED
BY A SIMPLE SUGAR
Clinical studies have shown that a deviation from glycemic
homeostasis, or hyperglycemia, is the main etiology for
the development of diabetes and diabetes complications
(The Diabetes Control and Complications (DCCT) Trial
Research Group, 1993, 1998). Glycemic homeostasis is a
collective, harmonized process that involves a network of
hormones, peptides, and neurotransmitters, and the most critical
physiological function is that of insulin.
In healthy individuals, insulin tightly controls blood glucose
within a particular range, postprandial or otherwise. In T1D,
insulin is absent from the circulation and has to be replaced. In
T2D, there is a shortage of insulin. However, insulin is not the
only hormone relevant to glucose homeostasis. For instance, the
glucagon hormone that is produced by pancreatic α cells, which
increases liver glucose production, is essential formaintaining the
glucose level within healthy limits. It has been reported that the
manipulation of glucagon by receptor agonists, such as glucagon-
like peptide-1 (GLP-1), or by dipeptidyl peptidase-4 (DPP-4)
inhibitors can decrease glucagon levels and eventually reduce
the degree of hyperglycemia and its associated risks (D’Alessio,
2011; Park et al., 2015). Incretin, or hormone glucose-dependent
insulinotropic peptide (GIP), is yet another critical hormone in
glucose homeostasis and stimulates glucagon secretion and the
eventual state of hyperglycemia.
Another class of drugs that directly reduces hyperglycemia is
sodium-glucose cotransporter type 2 (SGLT2) inhibitors. This
family includes dapagliflozin, empagliflozin, canagliflozin, and
gliflozin. These compounds act by blocking glucose reabsorption
by proximal tubules in the kidney. They reportedly improve the
glycemic index and contribute to weight loss in animal models of
diabetes (Liang et al., 2012) and in diabetic patients (Oguma et al.,
2015).
The SGLT2 knockout model has shown that blocking glucose
absorption in the kidneys can preserve the β cell population and
decrease cell death (Jurczak et al., 2011). There is also evidence
that using SGLT2 blockers can preserve β cell mass and function
(Hansen et al., 2014). However, the FDA warns of an increase in
the incidence of ketoacidosis associated with the use of SGLT2
inhibitors. The long-term use of this drug class requires further
study (Kibbey, 2015).
HYPERGLYCEMIA AND APOPTOSIS
In diabetes, β cell death can be mediated by various etiological
factors, including the exposure of cells to glucotoxicity (e.g.,
hyperglycemia and carbohydrate metabolites), lipotoxicity (e.g.,
triglycerides, LDL, cholesterol, and oxidation products), and pro-
inflammatory mediators (e.g., cytokines). Of all the factors noted
above, hyperglycemia is the most notable contributor; it is the
hallmark of diabetes and the smoking gun (Figure 3). It has been
reported that chronic exposure to hyperglycemia alone is capable
of initiating apoptotic β cell death in cell cultures and animal
models (Elmore, 2007; Marroqui et al., 2015), and this has also
been observed in humans through autopsy (Butler et al., 2003).
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FIGURE 3 | Apoptotic signals and cascades in pancreatic β cells. This figure was graciously provided by Helen Thompson and Jibran Wali, Islet Biology
Laboratory, St Vincent’s Institute, Australia.
Although programmed cell death is well studied and the
cascades and pathways are well mapped, the pathways by which
hyperglycemia activates β cell death in diabetes are not entirely
understood. It has been reported that hyperglycemia can produce
dose-dependent programmed cell death in β cell cultures. One
study has shown that when MIN6N8 (insulinoma) cells are
exposed to hyperglycemia (33.3mmol/l glucose), significant
programmed cell death occurs in a time- and dose-dependent
fashion when compared with cells incubated with 5.5mmol/l
glucose (Kim et al., 2005).
There is also evidence that chronic hyperglycemia in β
cell cultures activates the Bad genes, which are proapoptotic.
Bad transcription factors are dual-purpose, in that they
simultaneously activate apoptotic genes and inhibit the survival
pathways of cells; their action depends on their state of
phosphorylation (Datta et al., 2002; Wali et al., 2013).
Mitochondria are directly involved in apoptosis, but the exact
signals and events occurring in β cell mitochondria that lead
to cell failure are still under investigation. Apoptosis involves
multiple mechanisms, including the depolarization of the outer
mitochondrial membrane, the opening of the permeability
transition pore (PTP) in the inner membrane, the eﬄux of
cytochrome c, the release of Ca2+ from the mitochondrial
storage site, and the release of a 50-kDa apoptosis-inducing
factor (Heiskanen et al., 1999). Moreover, β cell apoptosis can be
initiated via different factors, such as signals from surrounding
cells (Kikuta et al., 2013; Mcllwain et al., 2013), mitochondrial
energy substrates, or metabolites such as inorganic phosphates
(Pramanik et al., 2011).
To better understand the etiology of β cell death by apoptosis
in diabetes, the mechanisms have been classified, according
to etiology, as intrinsic events (via mitochondria), or extrinsic
events (via receptors; Figure 3). For instance, apoptosis can be
instigated by hyperglycemia, obesity, inflammatory mediators,
or beta amyloid peptides (Wali et al., 2013). All of the above
factors, alone or in-combination, have the ability to trigger
apoptotic cell death, yet hyperglycemia has been shown to be
the most likely culprit in β cell apoptosis. T2D is a progressive
disease, patients are frequently exposed to hyperglycemia, and
each episode triggers more β cell apoptosis.
Clinically, almost all therapeutic agents used for the treatment
of T2D manipulate hyperglycemia either directly or indirectly;
the question is whether they can also preserve β cell mass. There
is evidence that some therapeutic agents used for the treatment
of T2D have the ability to reduce β cell apoptosis, aside from
other pharmacological properties. For instance, an in vitro study
has shown that thiazolidinediones are capable of inhibiting β
cell apoptosis induced either by a combination of hyperglycemia
(25mM glucose) and 0.5mM palmitate (Han et al., 2008) or by
cytokines (Chou et al., 2007; Li et al., 2010).
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ERS AND MITOCHONDRIAL FUNCTION
As demonstrated in Figure 3, numerous pathways can mediate
β cell death, but most of the mechanisms either finish or start
with the mitochondria. Mitochondria oversee energy production
through two main processes: the electron transport chain
reaction and oxidative phosphorylation (Lin and Beal, 2006).
The process of energy production is reportedly concurrent with
proton and electron leaks that eventually facilitate the generation
of different types of reactive oxygen species (ROS; Cadenas and
Davies, 2000; Jastroch et al., 2010; Affourtit et al., 2012). The
class of ROS includes the superoxide ion (O−2 ), the hydroxyl
radical (OH−), and nitric oxide (NO−) as well as the non-radicals
hydrogen peroxide (H2O2), singlet oxygen (O2), hypochlorous
acid (HOCl), and peroxynitrite (NO−3 ; Vara and Pula, 2014).
It is believed that at a basic level, ROS can serve as
physiological signals (Zorov et al., 2014). However, if the
production of ROS exceeds cell capacity, these reactive species
can substantially damage cell components, including the
mitochondria, via lipid peroxidation, protein oxidation, and
DNA mutation (Pacher et al., 2007).
In the pancreas, ROS can further contribute to β cell failure
by damaging the apparatus that is essential for insulin synthesis
or by depleting the energy required for this process (Lagouge and
Larsson, 2013). Animalmodels of T2D have shown an association
of diabetes with the production of ROS (Carlsson et al., 1999;
Ihara et al., 1999; King, 2012). In vitro β cell culture studies have
supported this observation along with other signs of β cell failure,
such as a significant depletion of cellular energy and cell death (Fu
et al., 2015).
Many clinical studies have shown a pattern of hyperglycemia
that is associated with ROS (Tessier et al., 1999; Marra et al.,
2002); β cells, in particular, have a low capacity to avoid
damage caused by ROS because these cells have the lowest
expression of antioxidant enzymes, such as superoxide dismutase
(SOD), catalase, and glutathione peroxidase (Lenzen et al., 1996).
Furthermore, the overexpression of antioxidant enzymes, such as
glutathione peroxidase-1 (GPx-1), in an animal model of diabetes
provided protection against hyperglycemia-induced oxidative
stress (Harmon et al., 2009). Some animal models and in vitro
studies have shown that some antioxidants can ameliorate cell
damage in diabetes (Kaneto et al., 1999; Koya et al., 2003).
More specifically, by targeting the mitochondria, the
antioxidant mitoquinone (MitoQ) exerts a protective effect
against glucotoxicity-induced β cell apoptosis (Lim et al.,
2011). Mitoquinone is a member of a new therapeutic class
of antioxidants that specifically targets the mitochondria; it
is a ubiquinone derivative designed to accumulate in high
concentrations in the mitochondrial matrix (Smith et al., 2003).
Another mitochondria-targeting agent is ruboxistaurin, an orally
active protein kinase C beta inhibitor (PKCI) that has been tested
in diabetes complication trials (Bansal et al., 2013; Tuttle et al.,
2015). Ruboxistaurin is reportedly effective for the prevention of
retinopathy (Gogula et al., 2013), renopathy (Alicic and Tuttle,
2014), and peripheral neuropathy (Vinik et al., 2005; Bansal et al.,
2013). However, some clinical trials testing ruboxistaurin as well
as other non-specific antioxidants, such as vitamin E, vitamin C,
coenzyme Q10, alpha lipoic acid, and L-carnitine, have failed to
show any beneficial clinical effects (Golbidi et al., 2011).
The pharmacodynamics of PKCIs in clinical trials are not
clearly understood (Mochly-Rosen et al., 2012). Ruboxistaurin
has not yet been approved by the FDA, and further studies are
required to demonstrate its efficacy (Bansal et al., 2013; Sheetz
et al., 2013). The argument against PKCI use is based on the
fact that kinases are involved in almost all cell functions, and
finding a selective PK iso-enzyme inhibitor is a particularly
challenging task. The role of protein kinases and their inhibitors
in the β cell mass is also not entirely clear. However, evidence
suggests that the overexpression of PKC delta increases β cell
proliferation via an increase in the phosphorylation of p21.
Furthermore, under stressful conditions, PKC delta activates its
proapoptotic function and can mediate apoptotic β cell death
(Ranta et al., 2011).
Autophagy
The processes of cell injury and apoptosis are associated with
a phenomenon known as autophagy, a process by which
cells eliminate damaged organelles via lysosomal degradation
and facilitate new cell component turnover. Recently, it has
been proposed that the etiology of several diseases, including
diabetes, might involve a dysfunction of the autophagy process.
Studies of the relation between diabetes and autophagy have
shown that when β cells and human islet cells are exposed to
high levels of glucose or lipids, the process of autophagy is
blocked; subsequently, oxidized, damaged, ormis-folded proteins
accumulate in the cells. These sequential events result in signs of
β cell stress and failure (Fujimoto et al., 2009; Lee et al., 2012; Mir
et al., 2015).
Various signals regulate autophagy. One class of proteins
has been reported to be part of the autophagy machinery;
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)
proteins. mTOR proteins are kinases that are involved in several
cellular processes, including insulin resistance, adipogenesis,
angiogenesis, and autophagy (Laplante and Sabatini, 2009).
These kinases are thought to be upregulated in certain diseases
and involved in dysfunctional autophagy. With respect to
pancreatic β cells, it has been reported that when β cells are
incubated with rapamycin, the cells undergo autophagy and signs
of glucose impairment appear. When β cells are incubated with
3-methyladenine, which inhibits autophagy, cell viability returns
to normal (Tanemura et al., 2012). Recent animal studies have
shown that the onset of diabetes may be associated with protein
misfolding, a compromised autophagy process and endoplasmic
reticulum stress (ERS; Quan et al., 2012; Fu et al., 2015; Maiese,
2015).
Protein Misfolding
Endoplasmic reticulum (ER) protein misfolding has drawn
considerable attention in recent years as a possible etiology for
several chronic diseases, including diabetes, non-alcoholic fatty
liver disease, cancer, and Alzheimer’s disease. The ER is one of
the organelles responsible for storing Ca2+ as well as for protein
folding, assembly, and biosynthesis. Moreover, in β cells, the ER
is the site of insulin biosynthesis (Harding and Ron, 2002). The
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notion of ER stress in diabetes originated after several studies
concluded that during the pre-diabetic period, β cells entered
a hyper-active mode of pro-insulin synthesis, which led to an
increase in proteinmisfolding; themis-folded proteins eventually
accumulated at the ER and caused ERS (Kaufman, 2002; Dobson,
2003; Sitia and Braakman, 2003; Thomas et al., 2011; Kim et al.,
2012).
In the pre-diabetic stage, two processes occur: insulin
resistance and an overexpression of, proinsulin and unfolded
protein species in the ER lumen (Ron and Walter, 2007;
Fonseca et al., 2011). The accumulation of mis-folded proteins
is believed to lead to the ERS of β cells and is associated with an
inability to clear mis-folded proteins or dysfunctional autophagy.
This process is associated with a substantial generation of
ROS, apoptosis and β cell death (Contreras et al., 2003).
A stressful event triggers a stress signal, which subsequently
activates a downstream network known as the unfolded
protein response (UPR; Karaskov et al., 2006; Chambers et al.,
2007). Two transmembrane kinases, IREI and PERK, and one
transcription factor, ATF6, have been identified within the
sensory nexus of the membrane; in the case of stress, these
kinases send signals to halt protein translation, increase protein
folding, enhance cell autophagy, and initiate cell apoptosis
(Papa, 2015).
The latter process can be mediated either through the
activation of a CCAAT/enhancer-binding homologous protein
(CHOP; Yu et al., 2015) or through the activation of apoptosis
signaling kinases (Eitel et al., 2003), a process by which the body
recycles damaged proteins (Eitel et al., 2003).
All of the above mechanisms are aspects of cell repair and
maintenance (Laybutt et al., 2007). Unraveling the sequence
of these events should improve the potential for therapeutic
intervention (Cohen and Kelly, 2003). For instance, ERS can be
reversed using liraglutide, which prevents ERS-induced apoptosis
in β cells (Zhao et al., 2013).
The upstream controlling signals that initiate ERS can include
frequent hyperglycemia (Prentki and Nolan, 2006), high levels of
free fatty acids and inflammatory cytokines (Cardozo et al., 2005).
Mitochondria and the ER are major regulators of intracellular
Ca2+ levels. Any interference with Ca2+ storage or homeostasis
can trigger a second sequence of pathological processes that alter
normalmetabolism and can lead to cell death (Giorgi et al., 2012).
The proper functioning of β cells is reportedly disrupted
by abnormal Ca2+ levels; for instance, insulin exocytosis from
storage granules depends on the Ca2+ level, a process that is
highly unregulated in diabetes (Fonseca, 2009). Insulin release
from β cells can be stimulated by glucose levels and mediated
by Ca2+ levels. The latter enters cells via voltage-dependent
Ca2+ channels, which then activate several kinases, and the main
insulin release signaling is carried out via Ca2+/calmodulin-
dependent protein kinase II (CaMKII; Tabuchi et al., 2000).
CaMKII activity is tightly correlated with diabetes symptoms,
and inhibition of the enzyme complex reportedly produces an
impaired glucose tolerance (Dadi et al., 2014); β cells store Ca2+
in mitochondria and the ER, and damage to either organelle can
greatly alter both Ca2+ levels and insulin release (Dixit et al.,
2013).
β CELL GRAFTING AND PANCREAS
PLASTICITY
At present, there are two branches of diabetes research. The first
is directed toward understanding the factors influencing β cell
mass maintenance and preservation, which will directly benefit
T2D patients by making products that can preserve β cell mass
available. This group of products includes those such as amylin
agonist pramlintide, GLP-1 receptor agonists, and dipeptidyl
peptidase-4 (DPP-4) inhibitors (Godoy-Matos, 2014), and many
other products are under development. The second research
branch is concentrated on developing an understanding of how
to increase β cell mass in vitro for the sole purpose of pancreatic
transplantation or grafting.
The best example is the Edmonton protocol, in which
pancreas islets are transplanted into T1D patients (Shapiro et al.,
2000). Many breakthroughs have been made in this particular
area of research, such as the transplantation of a bio-artificial
pancreas that provides special shielding for the β cell graft against
the recipient immune system, which is a technology known as
βAir (Street et al., 2004; Barkai et al., 2013). This technique is
currently being tested in clinical trials. The original target for
pancreas transplantation was T1D; however, animal studies have
demonstrated that β cell grafting (partial transplanting) is also
a possible avenue of exploration for T2D patients (Close et al.,
2005).
CONCLUSION
Diabetes is a chronic metabolic disorder that is an epidemic
problem. Its pathophysiology revolves around a unique
phenomenon of programmed β cell death. The study of both
normal β cell mass growth and β cell mass pathophysiology
is essential for the design of any intervention. Pancreatic cells
influence one another’s survival, and their growth is guided by
signals that affect cell development and phenotyping.
The adult human pancreas has a limited stock of β cells,
which, in diabetess, is ccontinuously exposed to insults, leading
to a decrease in mass. To replenish these cells or to replace
them by grafting, more research is required to pinpoint the
exact mechanism associated with β cell death and the factors
affecting cell proliferation. Several pharmacological agents have
been shown to restore β cell mass. However, clinically, many
of these compounds are associated with side effects. Current
evidence directly implicates mitochondria in the β cell death in
diabetes. Therefore, understanding the role of mitochondria and
mitochondrial agents in preserving the insulin secretion of β cells
is critical. Our understanding of the pathophysiology of the β
cell death associated with obesity, hyperglycemia or other causes
should provide key information for the development of more
specific agents for preserving β cell mass.
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